
AnaptysBio’s etokimab fails in moderate-to-severe atopic dermatitis
pharmafile | November 11, 2019 | News story | Sales and Marketing | AnaptysBio; atopic dermatitis, pharma
AnaptysBio has announced disappointing new Phase 2b data for its anti-IL-33 candidate etokimab in the treatment of moderate-to-severe atopic dermatitis.
The company revealed that, in a study of 300 adult participants, the drug had failed to show superior benefit in the treatment of the condition according to the Eczema Area and Severity Index (EASI) after 16 weeks of treatment compared to placebo, falling short of the trial’s primary endpoint.
“We are surprised and very disappointed by the topline results of the ATLAS trial,” said Hamza Suria, President and Chief Executive Officer of AnaptysBio. “We would like to thank all involved in the participation and support of the ATLAS study, including the patients, the investigators, their staff and our employees. We look forward to continuing our strategy of advancing our wholly-owned clinical and preclinical pipeline programmes.”
The news has led AnaptysBio to halt another Phase 2b trial investigating the drug in the treatment of eosinophilic asthma in around 400 patients. However, the company confirmed that another trial, investigating around the drug’s efficacy in approximately 100 participants with chronic rhinosinusitis with nasal polyps will continue, with interim analysis results expected in the first quarter of 2020.
Matt Fellows
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …

Bend Bioscience adds commercial spray drying facility to Georgia site
Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …





